Arcturus plans Phase II dosing of ARCT-2601 next quarter, top line data in 2H 2027
FROM THE WIRE · SEEKINGALPHA.COM
Arcturus Q3 2026 earnings: ARCT-032 and ARCT-2601 updates, LUNAR 2.0 progress, and cash runway through 2028.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralClinical development updates and cash runway bear on the stock valuation.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Arcturus plans Phase II dosing of ARCT-2601 next quarter.
- 02Top line data are expected in 2H 2027.
- 03Cash runway extends through 2028.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets